Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
258 8 |
Ultima descărcare din IBN: 2024-04-21 15:43 |
Căutarea după subiecte similare conform CZU |
616.36-002-08 (11) |
Заболевания пищеварительной системы. Болезнь пищеварительного тракта (1732) |
SM ISO690:2012 ANGHEL, Ludmila, SCUTARI, Corina, DUBCENCO, Valeriu, BODRUG, Elena, PEREDELCU, Rodica. Studiul managementului hepatitei virale C. In: Revista Farmaceutică a Moldovei , 2022, nr. 1(49), pp. 30-35. ISSN 1812-5077. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista Farmaceutică a Moldovei | ||||||
Numărul 1(49) / 2022 / ISSN 1812-5077 | ||||||
|
||||||
CZU: 616.36-002-08 | ||||||
Pag. 30-35 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Viral hepatitis C (VHC) is one of the leading causes of chronic liver disease and the overall prevalence of infection in 2019 has been estimated at approximately 1%. The aim of this study was to investigate the efficacy and tolerability of different antiviral drugs in the treatment of VHC. Data on the treatment of VHC in the National Programme for the Control of Viral Hepatitis were analysed. The clinical study was conducted in the Hospital for Infectious Diseases Toma Ciorbă during 2020-2021. The use of treatment with direct-acting antivirals is successful, with a failure rate of less than 0.5%, but also more than 6% among genotype 3. For patients resistant to the treatment regimens used in the National Programme, the use of genotype-specific treatment, as recommended by the European Association for the Study of the Liver (EASL), is required. Based on the study of disease records, the Declatasvir + Sofosbuvir and Sofosbuvir + Ribavirin regimens for chronic VHC show treatment efficacy of about 98% and 87.3 respectively for 12-24 weeks. |
||||||
Cuvinte-cheie words: viral hepatitis, management, antiviral drugs, hepatită virală, management, preparate antivirale |
||||||
|